Study S002770

An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NNC0174-0833 in Subjects With Normal Renal Function and Impaired Renal Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04209049
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 33
Start: 2020-01-15
Primary completion: 2021-01-05
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity
Interventions: DRUG:NNC0174-0833
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1228-9001

Registered primary outcomes

Area under the plasma NNC0174-0833 concentration-time curve after a single dose [From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003002	Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide. Nielsen MJF, Clinical pharmacokinetics	2026	Other trial	PMID 42228334 DOI	cites ClinicalTrials.gov:NCT04209049; registry reference DERIVED:42228334